NO993520L - Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon - Google Patents
Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjonInfo
- Publication number
- NO993520L NO993520L NO993520A NO993520A NO993520L NO 993520 L NO993520 L NO 993520L NO 993520 A NO993520 A NO 993520A NO 993520 A NO993520 A NO 993520A NO 993520 L NO993520 L NO 993520L
- Authority
- NO
- Norway
- Prior art keywords
- erectile dysfunction
- better
- methods
- dosage forms
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9700878.3A GB9700878D0 (en) | 1997-01-17 | 1997-01-17 | Dosage forms and method for ameliorating male erectile dysfunction |
PCT/GB1998/000143 WO1998031368A1 (en) | 1997-01-17 | 1998-01-16 | Dosage forms and method for ameliorating male erectile dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
NO993520D0 NO993520D0 (no) | 1999-07-16 |
NO993520L true NO993520L (no) | 1999-09-16 |
Family
ID=10806104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO993520A NO993520L (no) | 1997-01-17 | 1999-07-16 | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon |
Country Status (27)
Country | Link |
---|---|
US (2) | US6342246B2 (no) |
EP (1) | EP0954314B1 (no) |
JP (1) | JP2000513736A (no) |
KR (1) | KR100416768B1 (no) |
CN (1) | CN1243440A (no) |
AT (1) | ATE211385T1 (no) |
AU (1) | AU717337B2 (no) |
BG (1) | BG103570A (no) |
BR (1) | BR9808888A (no) |
CA (1) | CA2276758A1 (no) |
DE (1) | DE69803360T2 (no) |
DK (1) | DK0954314T3 (no) |
EE (1) | EE03805B1 (no) |
ES (1) | ES2167061T3 (no) |
GB (1) | GB9700878D0 (no) |
HU (1) | HUP0001089A3 (no) |
IL (1) | IL130714A0 (no) |
NO (1) | NO993520L (no) |
NZ (1) | NZ336436A (no) |
PL (1) | PL334656A1 (no) |
PT (1) | PT954314E (no) |
RU (1) | RU2204413C2 (no) |
SK (1) | SK283301B6 (no) |
TR (1) | TR199901669T2 (no) |
UA (1) | UA62954C2 (no) |
WO (1) | WO1998031368A1 (no) |
YU (1) | YU33099A (no) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
GB9813278D0 (en) * | 1998-06-20 | 1998-08-19 | Medical Res Council | Male contraceptive |
JP2000178204A (ja) * | 1998-10-05 | 2000-06-27 | Eisai Co Ltd | ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤 |
CA2251255A1 (en) * | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
WO2001076602A1 (en) | 2000-04-07 | 2001-10-18 | Tap Pharmaceutical Products Inc. | Apomorphine derivatives and methods for their use |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
WO2002017927A1 (en) * | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Inc. | Method for treating erectile dysfunction and increasing libido in men |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20020103105A1 (en) * | 2000-11-22 | 2002-08-01 | Brioni Jorge D. | Use of selective dopamine D4 receptor agonists for treating sexual dysfunction |
US7022728B2 (en) | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
US20030008878A1 (en) * | 2001-03-09 | 2003-01-09 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
US20020169166A1 (en) * | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
FR2834894B1 (fr) * | 2002-01-21 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de piribedil |
FR2834897B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de testosterone |
AU2003215461A1 (en) * | 2002-03-26 | 2003-10-08 | Bernard Charles Sherman | Stable tablets comprising pergolide mesylate |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
US20040156894A1 (en) * | 2003-02-07 | 2004-08-12 | Grother Leon Paul | Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
US20050137265A1 (en) * | 2003-03-31 | 2005-06-23 | Haley Eugene T. | Rapidly dissolving metoclopramide solid oral dosage and method thereof |
ES2359977T3 (es) | 2003-03-31 | 2011-05-30 | Titan Pharmaceuticals, Inc. | Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina. |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
EP2979699A1 (en) * | 2005-04-15 | 2016-02-03 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
PT2450041T (pt) | 2005-10-12 | 2018-11-16 | Unimed Pharmaceuticals Llc | Gel de testosterona melhorado e método para a sua utilização |
WO2008008120A1 (en) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
US8861813B2 (en) * | 2008-03-13 | 2014-10-14 | Mallinckrodt Llc | Multi-function, foot-activated controller for imaging system |
US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
US8545879B2 (en) | 2009-08-31 | 2013-10-01 | Wilmington Pharmaceuticals, Llc | Fast disintegrating compositions of meloxicam |
SG174465A1 (en) | 2009-10-30 | 2011-10-28 | Ix Biopharma Pte Ltd | Fast dissolving solid dosage form |
CN101797260B (zh) * | 2009-12-23 | 2011-09-21 | 济南圣泉唐和唐生物科技有限公司 | L-阿拉伯糖在制备用于治疗阴茎勃起障碍药物中的用途 |
AU2011312107B2 (en) * | 2010-10-08 | 2016-06-23 | R.P. Scherer Technologies, Llc | Oral vaccine fast-dissolving dosage form using starch |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
BR112014030265A2 (pt) * | 2012-06-05 | 2017-06-27 | Neuroderm Ltd | composição farmacêutica líquida ou semissólida e método para tratar uma doença ou distúrbio neurológico ou de movimento. |
US20150342946A1 (en) | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3928566A (en) * | 1970-08-14 | 1975-12-23 | Du Pont | Lyophilized biological products |
US4098802A (en) * | 1975-02-18 | 1978-07-04 | Akzona Incorporated | Oral pharmaceutical preparation having androgenic activity |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5135752A (en) * | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
HUT75616A (en) * | 1992-03-17 | 1997-05-28 | Pfizer | Method for prooucing porous delivery devices |
SK91096A3 (en) * | 1994-01-27 | 1997-06-04 | Univ Oklahoma Board Of | Rapidly dissolving oral dosage form |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
DE69514794T2 (de) * | 1994-04-22 | 2000-07-27 | Pentech Pharmaceuticals, Inc. | Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion |
US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
-
1997
- 1997-01-17 GB GBGB9700878.3A patent/GB9700878D0/en active Pending
-
1998
- 1998-01-16 SK SK972-99A patent/SK283301B6/sk unknown
- 1998-01-16 AT AT98900902T patent/ATE211385T1/de not_active IP Right Cessation
- 1998-01-16 EE EEP199900288A patent/EE03805B1/xx not_active IP Right Cessation
- 1998-01-16 DK DK98900902T patent/DK0954314T3/da active
- 1998-01-16 NZ NZ336436A patent/NZ336436A/xx unknown
- 1998-01-16 RU RU99117926/14A patent/RU2204413C2/ru not_active IP Right Cessation
- 1998-01-16 PT PT98900902T patent/PT954314E/pt unknown
- 1998-01-16 AU AU56710/98A patent/AU717337B2/en not_active Ceased
- 1998-01-16 TR TR1999/01669T patent/TR199901669T2/xx unknown
- 1998-01-16 IL IL13071498A patent/IL130714A0/xx unknown
- 1998-01-16 EP EP98900902A patent/EP0954314B1/en not_active Expired - Lifetime
- 1998-01-16 YU YU33099A patent/YU33099A/sh unknown
- 1998-01-16 CA CA002276758A patent/CA2276758A1/en not_active Abandoned
- 1998-01-16 JP JP10533951A patent/JP2000513736A/ja active Pending
- 1998-01-16 WO PCT/GB1998/000143 patent/WO1998031368A1/en not_active Application Discontinuation
- 1998-01-16 PL PL98334656A patent/PL334656A1/xx unknown
- 1998-01-16 BR BR9808888-2A patent/BR9808888A/pt not_active Application Discontinuation
- 1998-01-16 KR KR10-1999-7006492A patent/KR100416768B1/ko not_active IP Right Cessation
- 1998-01-16 DE DE69803360T patent/DE69803360T2/de not_active Expired - Fee Related
- 1998-01-16 UA UA99084671A patent/UA62954C2/uk unknown
- 1998-01-16 CN CN98801849A patent/CN1243440A/zh active Pending
- 1998-01-16 HU HU0001089A patent/HUP0001089A3/hu unknown
- 1998-01-16 ES ES98900902T patent/ES2167061T3/es not_active Expired - Lifetime
-
1999
- 1999-07-12 BG BG103570A patent/BG103570A/bg unknown
- 1999-07-12 US US09/352,515 patent/US6342246B2/en not_active Expired - Fee Related
- 1999-07-16 NO NO993520A patent/NO993520L/no unknown
-
2001
- 2001-12-24 US US10/026,492 patent/US20020156056A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
RU99117926A (ru) | Лекарственные формы и способ лечения расстройства мужской эректильной функции | |
MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
UA84266C2 (uk) | Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування | |
EP1708685A4 (en) | GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES | |
WO2004112711A3 (en) | Oral extended-release composition | |
HUP0203733A2 (en) | Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
HUP0101543A2 (hu) | Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények | |
MXPA02012793A (es) | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. | |
AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
SE0102276D0 (sv) | Device and method for the administration of a medicament | |
TW200503782A (en) | New formulations and use thereof | |
BG108516A (en) | Pharmaceutical formulation | |
ATE287264T1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
AU9551201A (en) | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates | |
ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
HUP0402358A2 (hu) | Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására | |
SG145717A1 (en) | Composition for releasing a weak base for an extended period of time | |
ES2188513T3 (es) | Utilizacion de desoxipeganina para el tratamiento de la drogodependencia. | |
MY139719A (en) | Oral dosage form for controlled drug release | |
PE20011042A1 (es) | Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan |